Lupus & antiphospholipid syndrome
Role of intravenous immunoglobulins in the management of systemic lupus erythematosus: a single-centre experience
Authors' conclusion
Despite its high cost, intravenous IG has demonstrated effectiveness in treating refractory SLE, especially when there is haematological involvement.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) treated with intravenous immunoglobulin (IG)
- Participants
- 31 patients
- Outcome
- Effectiveness and safety of intravenous IG
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Changes in clinical and laboratory parameters after intravenous IG · end of treatment
- Acute phase values, proteinuria, complement levels and anti-dsDNA decreased significantly
- p<0.001
Observational data: associations, not effects.
Further findings
Indication for intravenous IG
- Haematological involvement (main indication)
- 20, 64.5%
- Thrombocytopenia
- 8, 25.8%
- Initiated mainly for refractory disease
Safety
Side effects
- In most cases mild, usually myalgia or fever
Original publication
Role of intravenous immunoglobulins in the management of systemic lupus erythematosus: a single-centre experience. Lupus Sci Med. Published 20 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →